| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRO | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -52.6K | -49.25% | 54.2K | Dec 12, 2023 | Direct | F1, F2 | ||
| transaction | MIRO | Common Stock | Disposed to Issuer | -54.2K | -100% | 0 | Dec 13, 2023 | Direct | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRO | Employee Stock Option (right to buy) | Disposed to Issuer | -100K | -100% | 0 | Dec 13, 2023 | Common Stock | 100K | $3.75 | Direct | F5 | ||
| transaction | MIRO | Employee Stock Option (right to buy) | Disposed to Issuer | -18.8K | -100% | 0 | Dec 13, 2023 | Common Stock | 18.8K | $3.75 | Direct | F5 | ||
| transaction | MIRO | Employee Stock Option (right to buy) | Disposed to Issuer | -25K | -100% | 0 | Dec 13, 2023 | Common Stock | 25K | $3.75 | Direct | F5 | ||
| transaction | MIRO | Employee Stock Option (right to buy) | Disposed to Issuer | -25K | -100% | 0 | Dec 13, 2023 | Common Stock | 25K | $3.75 | Direct | F5 | ||
| transaction | MIRO | Employee Stock Option (right to buy) | Disposed to Issuer | -25K | -100% | 0 | Dec 13, 2023 | Common Stock | 25K | $3.75 | Direct | F5 |
Paul Buckman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). |
| F2 | Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| F3 | Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. |
| F4 | In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
| F5 | In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |